Nimotop S (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels in the smooth muscle of cerebral arteries. By reducing calcium entry, it relaxes these vessels, increases cerebral blood flow, and limits calcium‑induced neuronal injury, thereby offering protective effects during ischemic events.

The dosage of Nimotop S is determined by the prescribing clinician based on the patient’s condition, severity, and individual response. Healthcare professionals adjust the regimen according to clinical guidelines and patient-specific factors.

Safety data for nimodipine in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should only be used if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To request Nimotop S, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimodipine is distinguished by its high affinity for cerebral vessels, offering targeted vasodilation and neuroprotection not typically seen with generic calcium channel blockers such as amlodipine. This makes it the preferred choice for managing cerebral vasospasm after subarachnoid hemorrhage.

Nimotop S should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nimotop S is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically directed by a healthcare professional. Administration timing follows the prescriber’s instructions.

Serious risks include significant hypotension, bradycardia, and rare allergic reactions such as rash, swelling, or anaphylaxis. Patients should be monitored for sudden drops in blood pressure or heart rate, and any signs of an allergic response require immediate medical attention.

Nimotop S is contraindicated in patients with known hypersensitivity to nimodipine or other calcium channel blockers. Caution is also advised for individuals with severe hepatic impairment, uncontrolled hypotension, or those taking interacting medications that could exacerbate blood pressure reductions.